First-in-class drug candidate for treatment of multiple myeloma and Diffuse Large B Cell Lymphoma

Reference number 4780

Sectors: Biotechnology

Industries: Therapeutics

DTP3 is a first-in-class GADD45β/MKK7 inhibitor targeting the NF-κB pathway

Proposed use

Multiple Myeloma (MM) and Diffuse Large B Cell Lymphoma (ABC-DLBCL) cells rely on aberrant NF-κB activity for survival. DTP3 disrupts this pathway, killing MM and ABC-DLBCL cells via JNK-driven apoptosis.

Additionally, GADD45β/MKK7 inhibition has been reported to be neuroprotective in two in vivo models of ischemia.

Problem addressed

There is significant clinical need for safer and more effective treatments for both MM and DLBCL. Current MM therapies rarely achieve lasting remissions, and are often too toxic for elderly patients or those with comorbidities. While more than 50% of DLBCL cases are cured with standard immuno-chemotherapy, patients who do not respond generally die from their disease.

Technology overview

The D-tripeptide DTP3 was developed through a peptide library screen to target the survival complex formed by the NF- κB regulated factor, GADD45β, and the JNK kinase MKK7.

DTP3 is highly specific and kills MM/ABC-DLBCL cells without damaging normal cells. It has a similar IC50 to the standard of care, bortezomib, but more than 100 times greater therapeutic index ex vivo.

Preclinical work has been completed, showing efficacy, specificity and tolerability, with wide safety margins.

In a proof-of-concept Phase I study, DTP3 induced markers for apoptosis in malignant CD138+ cells, but not in healthy CD20+ cells. The trial data suggests that patient stratification could occur through measurements of GADD45β expression and the extent of JNK-induced apoptosis in tumour cells.

Initially, it is envisaged that DTP3 will be introduced as salvage therapy in late-stage patients to alleviate toxicities, extend remissions and improve quality of life as a result of its enhanced safety profile and ability to bypass drug resistance.

Benefits

  • DTP3 inhibits GADD45β/MKK7  with sub-nanomolar activity
  • Target selective
  • Kills malignant CD138+ cells ex-vivo
  • Protective in murine models, with high plasma concentration and bioavailability
  • Good tolerability and no reported toxicity in humans
  • Biomarkers identified for patient stratification

Intellectual property information

This technology is filed in multiple territories and covers composition of matter and use (WO2011048390A2) with a separate patent family covering the patient stratification marker (WO2012118909A1).

Inventor

Professor Guido Franzoso

Centre Co-Director, Chair in Inflammation & Signal Transduction
Faculty of Medicine, Department of Immunology and Inflammation

Visit personal site

Contact us about this technology

4780 - contact

Contact

Stephanie Morris

Director of Industry Partnerships and Commercialisation, Medicine

Stephanie Morris is Director of Industry Partnerships and Commercialisation for the Faculty of Medicine at Imperial College London.

Contact Stephanie

+44 (0)20 7594 2717

stephanie.morris@imperial.ac.uk

Related technologies

A cytokine for wound healing and scar reduction

A cytokine for wound healing and scar reduction

A cytokine that promotes wound healing by accelerating re-epithelialization of the wound bed faster than FDA approved products. The treatment also has a potential to minimise scarring after injury. Find out more

A novel dimer system for single small molecule detection

A novel dimer system for single small molecule detection

A new method for the efficient and accurate detection of proteins with nanopores by utilising aptamer-modified gold nanoparticle (AuNP) Find out more

Active delivery of Zinc Fingers for in vivo enhancement of gene regulation

Active delivery of Zinc Fingers for in vivo enhancement of gene regulation

A universal method to enhance control of gene expression in vivo with artificial gene-regulatory transcription factors (TFs). Find out more

Sign up for updates

Sign up for monthly technology alerts via email, and find other ways to connect with us.

Loading...